Background. Troponin I (TnI) is an effective marker for detecting myocardial injury, but the interpretation of levels in the setting of end-stage renal disease (ESRD) is still unclear. TnI levels have been noted to be increased in 5-18% of asymptomatic haemodialysis (HD) patients with standard assays, but newer-generation, high-sensitivity assays have not been examined. In addition, there is limited data on the variability of TnI levels in patients over time as well as the effect of HD on TnI levels. The aim of this study was to prospectively explore the incidence of TnI with a highsensitivity assay, the variability of TnI levels over time and the effect of HD on levels. Methods. We enrolled 51 asymptomatic HD patients and checked TnI levels using a high-sensitivity assay. Levels were drawn pre-HD monthly for three consecutive months. As per manufacturer guidelines, levels were considered normal up to 0.034 ng/mL, indeterminate elevation (IE) if between 0.035 and 0.120 ng/mL and consistent with myocardial infarction (MI) if >0.120 ng/mL. In the third month, post-HD TnI was also drawn to determine change with dialysis. Results. At baseline, median TnI level was 0.025 ng/mL (range, 0-0.461 ng/mL). Baseline TnI levels were normal in 63% and elevated (≥0.035 ng/mL) in 37%. Of those with elevations, 79% were in the IE range and 21% in the acute myocardial infarction range. Higher TnI levels at baseline were associated with a history of coronary artery disease, left ventricular hypertrophy, lower cardiac ejection fraction and higher serum phosphate levels. Average incidence of elevated TnI was 41% over the 3 months. Thirty-six patients had stable levels without a change in classification over 3 months. Twelve varied over time. Forty-five (94%) had no change in classification pre-and post-HD. Conclusion. Using a new-generation, high-sensitivity assay, over a third of asymptomatic ESRD patients have an elevated TnI. The significance of these low-level elevations is unclear at this time. TnI levels remain stable over a 3-month period in most patients. HD treatment does not appear to affect the TnI level.
Introduction
Cardiac troponins have become established as a gold standard in the diagnosis of myocardial injury. End-stage renal disease (ESRD) patients have been noted to have a high incidence of baseline elevations of troponins, making the diagnosis of acute myocardial damage more difficult. Troponin I (TnI) has generally been favoured in the ESRD population because of a somewhat lower incidence of elevations (5-18%) [1, 2] .
There have also been conflicting reports about the effect of haemodialysis (HD) itself on troponin levels. Some studies have shown a decrease in TnI after a HD treatment [3, 4] and some showed no effect [5] .
Virtually all the data on TnI levels in ESRD patients have been derived using older-generation assays, and problems with assay standardization have been noted [6] . However, over the past several years, high-sensitivity assays have been introduced that have improved accuracy for the diagnosis of myocardial infarction (MI) [7, 8] .
Our institution switched to a high-sensitivity TnI assay in 2008. We decided to explore the incidence of TnI elevations in asymptomatic HD patients with this new assay. We also set out to determine whether TnI levels change with HD. Finally, as there is limited data on individual variability in HD patients, we also decided to evaluate the degree to which TnI levels vary over several months in the same patients.
Materials and methods
Asymptomatic HD patients undergoing chronic HD three times a week at our institution's outpatient HD unit were eligible to participate. All patients in the first three shifts of the Monday, Wednesday and Friday schedule were screened for inclusion. Asymptomatic patients were defined as patients with no acute coronary syndrome (ACS) or self-reported angina symptoms in the preceding 4 weeks. TnI levels were measured using a high-sensitivity Vitros ES assay manufactured by Ortho Clinical Diagnostics. The manufacturers' stated detection limit is 0.012 ng/mL. The 99th percentile upper reference limit is 0.034 ng/mL with a reported im-precision of 10% coefficient of variation at 0.034 ng/mL, so >0.034 ng/mL was considered a positive test. A concentration of 0.120 ng/mL was the clinical cutoff for 'acute myocardial infarction' (AMI) based on the ROC curve for optimal diagnostic sensitivity and specificity. Levels between 0.035 and 0.120 ng/mL were considered 'indeterminate elevation' (IE).
TnI levels were drawn pre-dialysis in all patients for three consecutive months at the time of their routine monthly blood draw. At the third month, post-dialysis TnI was drawn as well to determine change after dialysis. Data were collected from chart review and patient interviews for baseline clinical data and follow-up during the 3-month study period.
Statistics
Demographic and clinical characteristics were compared between the group of patients who had elevated TnI at baseline and the group of patients with normal values. Data were examined for normality, and statistical tests along with presentation of results were chosen accordingly. Categorical data are presented as percentages and compared with the Fisher's exact test. Continuous normally distributed data are presented as mean ± standard deviation and were analysed with the independent samples t-test. Data that were not normally distributed were analysed by the Mann-Whitney U-test and presented as median values (min, max). TnI values over time and before and after dialysis were compared 
Results

Baseline characteristics
Baseline TnI levels were drawn pre-HD in a total of 51 patients. Figure 1 is a flow chart for study enrolment. At baseline, the median TnI level was 0.025 ng/mL (range, 0-0.461 ng/mL). Baseline TnI levels were normal in 63% of patients and elevated (≥0.035 ng/mL) in 37%. Of those with elevated TnI, 15 out of 19 (79%) were in the IE range and 4 out of 19 (21%) were in the AMI range. Baseline clinical data according to troponin positivity are described in Table 1 . Higher TnI levels at baseline were significantly associated with a history of coronary artery disease (CAD), left ventricular hypertrophy (LVH), lower cardiac ejection fraction (EF) and higher serum phosphate levels.
TnI variability
Three consecutive monthly troponin levels were available in 48 patients. None of the study patients had any cardiac event during the period of data collection. Three patients were excluded for the following reasons: one patient died of a stroke 3 weeks after initial enrolment, one patient had a kidney transplant in Month 2 and one patient was hospitalized in Month 2 for lower extremity cellulitis. In Month 1, as noted above, TnI was found to be elevated in 37% of patients. In Month 2, 44% had a positive TnI and TnI levels in asymptomatic patients on HD using a high-sensitivity assayin Month 3, 44% again had TnI elevation. Of patients with positive TnI, levels were in the AMI range in 4 out of 19 (21%), 2 out of 22 (9%) and 2 out of 21 (10%) over the 3 months, respectively. Maximal TnI levels each month were 0.481, 1.640 and 0.219 ng/mL, respectively. Thirty-six patients had stable levels without a change in classification over 3 months. Twelve patients had consistent elevations of TnI and 24 had consistently normal levels. Eleven of the 12 who had consistent elevations had an elevation in the IE range and one had consistent levels in the AMI range.
Twelve patients varied over time. Of these, seven with initially normal levels developed troponin positivity over the next 2 months (all in the IE range). Another five initially had positive TnI, which became normal in two and remained positive but changed category in three (IE to MI in one and MI to IE in two). Table 2 summarizes the frequency of positive troponins over the 3 months by category of elevation. There were no differences observed in TnI levels over the 3 months. The median of the standard deviation of TnI was 0.005 ng/mL (interquartile range, 0.009-0.011). Figures 2 and 3 are scatter plot diagrams showing that TnI levels were highly correlated for individual patients between Months 1 and 2 ( Figure 2 ) and between Months 2 and 3 ( Figure 3 ). Correlation coefficients (rho) were 0.92 (P < 0.001) and 0.87 (P < 0.001), respectively.
TnI levels and haemodialysis
Forty-eight patients had TnI levels drawn pre-and post-HD. Forty-five (94%) patients had no change in classification pre-and post-HD. Levels were 0.029 ng/mL (range, 0-0.219 ng/mL) before HD and 0.028 ng/mL (range, 0-0.214 ng/mL) after HD and were not significantly different. Figure 4 shows a scatter plot diagram of TnI levels before and after dialysis showing a high correlation in individual patients with a correlation coefficient (rho) of 0.91 (P < 0.001).
Discussion
To our knowledge, this is the first study to determine the incidence of TnI elevations in ESRD patients using a newgeneration, high-sensitivity TnI assay. We found a mean incidence of TnI elevation of 41% in asymptomatic chronic HD patients. This is much higher than the previously reported incidence of 5-18% [1, 2] with the conventional assays and is more comparable to the incidence reported with troponin T in ESRD patients [1] . Whilst it could be argued that this represents a shortcoming in the newer assay, it might also reflect the increased sensitivity of the assay. Troponin T was initially thought to be less useful in ESRD patients because of an increased incidence of elevation in asymptomatic patients. However, it has become recognized more recently that troponin T elevations may have more prognostic utility in this population [2] . The largest series in ESRD patients, by Apple et al. [1] , showed that an elevated troponin Twas more highly associated with long-term patient mortality over time than TnI. With a higher-sensitivity TnI assay, one might find that the predictive value is now enhanced. This study cannot answer this question, as we do not yet have long-term follow-up of our patients. The enhanced sensitivity of the assay could have implications in non-renal disease populations as well. Recent studies found a high accuracy of high-sensitivity TnI assays in patients with typical cardiac chest pain symptoms [7, 8] . However, the significance of an elevation of TnI elevation in patients without symptoms or with atypical symptoms is uncertain, and one might expect a higher number of positive tests with this assay.
We found that higher TnI levels at baseline were associated with a history of CAD, LVH, lower EF and higher serum phosphate levels. The association with higher serum phosphate levels could be a reflection of more cardiovascular disease which has been associated with hyperphosphataemia in kidney disease patients, possibly due to increased vascular calcification [9] [10] [11] . The significance of high-sensitivity TnI elevation in asymptomatic HD patients is unclear at this time, but further study of the outcomes in such patients over time is warranted.
As a significant proportion of asymptomatic patients with ESRD have troponin positivity with this assay, the diagnosis of ACS in this population may be more complicated. It has been suggested that familiarity with a patient's 'baseline' troponin level might aid in the rapid diagnosis of an ACS if the patient has a level that is higher than his baseline in the appropriate clinical setting [9] . However, there has been very limited data on whether patients indeed have a stable 'baseline'. One study showed that troponin T levels were relatively stable in ESRD patients with only 7% of patients having a change in diagnostic category at 8 months and 24% at 15 months [12] . We are not aware of any similar studies with TnI. We found that TnI levels were stable in 75% of ESRD patients over 3 months. This finding supports a suggested protocol of checking quarterly troponin levels to monitor patients' baseline levels. This would aid the diagnosis of ACS if an initial level is significantly above baseline in a symptomatic patient. It might also identify high-risk patients who maintain a persistently elevated level, especially if it is borne out that a high TnI level in asymptomatic patients is prognostic using the high-sensitivity assay. It is also important to note that only a small number of patients had levels in the AMI range and the maximal number was 1.640 ng/mL, so levels above this in a symptomatic patient should be taken quite seriously.
Reports have differed on the effect of HD on TnI levels. In one study by Wayand et al., cTnI values decreased by TnI levels in asymptomatic patients on HD using a high-sensitivity assay81-86% after dialysis [3] . In contrast to the above findings, Farkouh et al. found that a single HD treatment produced no significant change in the cTnI level's diagnostic classification [5] . We found that 94% of patients had stable cTnI levels without change in classification after dialysis with a high-flux membrane. Clinically, this is evidence that one does not need to be concerned with the timing of blood sampling in relation to HD when following TnI levels for a patient suspected of having an ACS.
Conclusion
In conclusion, in asymptomatic ESRD patients, most patients have a normal TnI level but many do have slight elevations in TnI using a new-generation assay. Levels remained stable over a 3-month period in most patients. Very few patients had elevations in the AMI range. HD treatment does not appear to affect the level. The significance of the lowlevel elevations seen in this study will remain unclear until further outcome studies are performed.
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